Prime Medicine, Inc.PRME

Prime Medicine reported $4.6 million in revenue for the full-year 2025 and a $49.1 million net loss in the first quarter of 2026, while burning $42.7 million in operating cash and leaving the company with $64.1 million in cash and $218.0 million in liabilities against $76.7 million in shareholders’ equity. The March 31 10-Q shows a negative EPS of $-0.28 and 177.1 million diluted shares outstanding, a capital structure that rewards dilution more than it rewards patience. (source: 10-K, period ending 2025-12-31; 10-Q, period ending 2026-03-31, SEC EDGAR, https://www.sec.gov/Archives/edgar/data/1894562/000162828026047590/prme-20260706.htm)

Prime Medicine’s website describes Prime Editing as a ‘DNA word processor’ that ‘search and replace’ disease-causing sequences without double-strand breaks, and the company touts a strategic license and broad collaboration with Bristol Myers Squibb plus a New England Journal of Medicine publication on PM359 for chronic granulomatous disease. Yet the 10-Q carries no revenue line from these partnerships, no product approvals, and no clinical sales; the filings do not disclose the timing or magnitude of any future cash flows from these deals. (source: Prime Editing description, https://primemedicine.com; PM359 clinical data, https://www.primemedicine.com/pipeline/; Bristol Myers Squibb collaboration, https://www.primemedicine.com/pipeline/)

The company spent $34.1 million on R&D in the March quarter and another $214,000 on property, plant, and equipment, while generating negative operating cash flow of $-42.7 million. The balance sheet still shows $64.1 million in cash and cash equivalents, but the equity cushion is thin at $76.7 million against $218.0 million in liabilities. The 8-K filed on July 8 2026 is silent on fresh capital; instead it records routine corporate notices, underscoring that the company’s liquidity story remains entirely dependent on the next funding round or partnership milestone rather than internally generated cash. (source: R&D expense $34.1M, PP&E $214,000, operating cash flow $-42.7M, assets, liabilities, equity, 10-Q, period ending 2026-03-31, SEC EDGAR; 8-K dated 2026-07-08, https://www.sec.gov/Archives/edgar/data/1894562/000162828026047590/prme-20260706.htm)

The company’s investor materials highlight a pipeline, a partnership with Bristol Myers Squibb, and a peer-reviewed publication, but the filings do not quantify any near-term revenues or cash receipts from these initiatives. The SEC companyfacts JSON and submissions JSON confirm that no 10-K or 10-Q guidance is provided, leaving investors to guess whether the next milestone is a clinical readout, a regulatory filing, or another capital raise. The absence of segment-level revenue, gross margins, or cash flow per program in the filings means the market must price the story on narrative rather than numbers. (source: SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001894562.json; SEC submissions JSON, https://data.sec.gov/submissions/CIK0001894562.json)

For readers tracking the gap between platform storytelling and filing reality, the most concrete datapoint remains the March quarter loss of $49.1 million on $4.6 million of revenue, a ratio that would make a venture capitalist blanch and a public equity analyst reach for the nearest sensitivity table. Until the filings show a revenue line that isn’t dwarfed by R&D or a cash flow profile that isn’t exclusively negative, the file remains a research grant in disguise rather than a commercial biotech. (source: 10-Q, period ending 2026-03-31, SEC EDGAR)

The company’s About page touts executive bios from Amgen, Gritstone, and DMC Global, yet the filings reveal no operational metrics that would allow an external reader to verify execution strength. The absence of segment-level breakdowns, customer concentration, or capex efficiency means the file is rich in credentials and short on KPIs. (source: About page, https://primemedicine.com/about/)